Research programme: filariasis therapeutics - CombinatoRx Singapore
Latest Information Update: 19 Apr 2013
At a glance
- Originator CombinatoRx Singapore; Liverpool School of Tropical Medicine
- Developer CombinatoRx Singapore
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Filariasis
Most Recent Events
- 19 Apr 2013 No development reported for Filariasis in Singapore (unspecified route)